Colecalciferol

WEDNESDAY, Dec. 4, 2024 -- Taking even high doses of supplementary vitamin D won't lower an older person's odds for type 2 diabetes , new research confirms. Vitamin D supplements may have other benefits, but in otherwise healthy folks with sufficient levels of the nutrient, "our findings do not suggest benefits of long-term moderate- or high-dose vitamin D 3 supplementation" in warding off type 2 diabetes, the team of Finnish researchers concluded. They published their findings Dec. 2 in the journal Diabetologia . The new research followed on data from other studies that had suggested that people with especially low levels of vitamin D might face a higher risk for diabetes. That was true for people who were already prediabetic, especially. So could a relatively high dose of vitamin D supplements help lower type 2 diabetes rates among people without prediabetes -- those at no special risk for the blood sugar disease? To find out, researchers led by Jirki Vyrtanen , from the University of Eastern Finland, randomly assigned nearly 2,300 people aged 60 or older to receive either placebo pills or 40 or 80 micrograms of vitamin D3 supplements per day, for five years. At the end of the five years, "105 participants developed type 2 diabetes: 38 in the placebo group, 31 in the group receiving 40 micrograms of vitamin D3 per day, and 36 in the group receiving 80 micrograms of vitamin D3 per day," according to a university news release. In other words, there were no significant differences in the rate at which people developed type 2 diabetes, regardless of how much supplemental vitamin D they took. Vytanen's team also saw no benefit from high-dose supplements on a person's blood sugar or insulin levels, or measures of overweight/obesity. The bottom line, according to the researchers: For any healthy, non-prediabetic person with healthy vitamin D levels, upping intake of the vitamin won't alter your odds for diabetes or its common risk factors. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

XLH can lead to rickets, a condition that results in weak or soft bones. Credit: CGN089 via Shutterstock. The UK’s National Health Service (NHS) is rolling out Kyowa Kirin ’s Crysvita (burosumab) for the treatment of adults with a rare bone disease called X-linked hypophosphataemia (XLH). The drug has been available for children with XLH since 2018 but will now be available for eligible adults on the NHS. The service will initially roll the drug out through around 20 specialist centres across England. Additionally, patients will be taught to give Crysvita in their own homes to reduce “unnecessary visits to hospitals”. XLH is a genetic disorder that leads to low phosphate levels in the blood. Phosphate is essential for the normal formation of bones and teeth in childhood and helps maintain bone strength in adults. Deficiency of the mineral can result in rickets, an increased risk of fractures, muscle weakness, and dental problems such as abscesses and tooth loss. Patients often experience chronic pain and mobility issues in the most severe cases. This move follows the UK’s National Institute for Health and Care Excellence (NICE) recommendation in August, where the pricing watchdog said that the treatment is a clinically and cost-effective use of NHS resources. This wasn’t always the case, as NICE previously rejected the drug for adults on the NHS in draft guidance released in December 2023. In the guidance, NICE commented on pivotal clinical trial data, saying that patients on “burosumab may have less pain and fatigue, and improved physical functioning” but added it was “not certain”. This deliberation came from the results of the Phase III CL303 trial (NCT02526160), which compared Crysvita to a placebo for 24 weeks. After this period, people on placebo switched to Crysvita, where treatment was continued for another 72 weeks. The trial met its primary outcome – with 94.1% of the treatment arm meeting a mean serum phosphate concentration above the lower limit of normal (2.5mg/dL), compared to 7.6% in the placebo arm. In the announcement accompanying the roll-out, Oliver Gardiner, trustee at charity XLH UK, said: “This is fantastic news for adults with XLH in the UK. This life-changing treatment is the first to tackle the underlying problem and will lessen the significant physical and emotional challenges that adults with XLH face on a daily basis.” The standard of care for patients with XLH was phosphate supplements or vitamin D, which doesn’t target the cause of the disease and can cause side effects such as stomach problems and kidney stones. Crysvita works by suppressing the hormone that causes low levels of phosphate and stabilising levels in the blood. According to GlobalData’s Pharma Intelligence Center, Crysvita will generate $2.4bn in revenue in 2030. GlobalData is the parent company of Pharmaceutical Technology.